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T hrough C anada’s complex system of prescription drug coverage, about 21% of Canadians are covered by public provincial or territorial drug plans, 3% by federal public 
coverage and 70% by full or partial private insurance.1 An esti­
mated 20% of Canadians are currently uninsured or under­
insured.2,3 Many have detailed the failings of this system of pre­
scription drug coverage to deliver equitable access to medicines 
across the country, its cost and administrative inefficiencies, sus­
tainability concerns, and challenges related to rational use and 
inappropriate prescribing.1–7 Provincial, territorial and federal 
governments currently administer public drug plans with varied 
approaches to coverage, lists of covered or reimbursed drugs 
and formularies.1,5 The medicines included on different public 
formularies overlap substantially.8
The recent final report of the Federal Advisory Council on the 
Implementation of National Pharmacare, the 2019 federal bud­
get and various other government reports have highlighted the 
need for a common national formulary to harmonize drug cover­
age across the country in the context of pharmacare policy 
change.1,9,10 A national essential medicines list has been con­
sider ed as a potential policy tool to reduce variabilities in priori­
tized medicines across the country, guide improved prescribing, 
ensure quality and safety of care, and improve efficiency of medi­
cine spending.11–13 The report of the Federal Advisory Council on 
the Implementation of National Pharmacare recommends that 
“federal, provincial and territorial governments launch national 
pharmacare by offering universal coverage for a list of essential 
medicines” as a basis for a national formulary that would set a 
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ABSTRACT
BACKGROUND: Policy approaches have 
been considered to address inconsistent 
and inequitable prescription drug cover­
age in Canada, including a national 
essential medicines list. We sought to 
explore key factors influencing the 
acceptability and feasibility of an essen­
tial medicines list in Canada.
METHODS: We conducted semistruc­
tured interviews with decision­makers 
and other key stakeholders from gov­
ernment or pan­Canadian institutions, 
civil society and the private sector 
across Canada. We analyzed data using 
inductive thematic analysis and by 
applying Kingdon’s Multiple Streams 
Framework to analyze the emergent 
themes deductively.
RESULTS: We conducted 21 interviews 
before thematic saturation was achieved. 
We categorized emergent themes to de­
scribe the problem, the essential medi­
cines list policy (including content and 
process), and politics. There was con­
sensus among participants that pre­
scription drug coverage was an impor­
tant problem to address. Participants 
differed in their views on how to define 
essential medicines and concerns 
about what would be excluded from an 
essential medicines list. There was con­
sensus on important features for a pro­
cess to develop an essential medicines 
list: an independent decision­making 
body, use of defined selection criteria 
based on quality evidence, and clear 
communication of the purpose of the 
essential medicines list. Federal govern­
ment financing and the broader pharma­
care model, engagement of various in­
terest groups and changing political 
agendas emerged as core political fac­
tors to consider if developing a Can adian 
essential medicines list.
INTERPRETATION: Although stakehold­
ers’ views on the content of a Canadian 
essential medicines list varied, there was 
consensus on the process to formulate 
and implement an essential medicines 
list or common national formulary, 
including choosing medicines based on 
best evidence. Greater understanding is 
now needed on how patients, clinicians 
and the public perceive the concept of an 
essential medicines list. 
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minimum level of coverage across Canada.10 Universal public 
coverage of an essential medicines list in Canada was estimated 
to result in $4.27 billion annual savings and cover most of the 
current medication needs in the country.14
Although national essential medicines lists have mostly been 
developed in low­and middle­income countries, at least 21 high­
income countries have essential medicines lists to carefully 
select medications that “satisfy the priority health care needs of 
the population,” such as the “Wise List” in Sweden.15–18 The World 
Health Organization (WHO) Model List of Essential Medicines 
serves as an international guide to help policy­makers set their 
national medicine priorities in their unique context.18
The perceptions of decision­makers and policy stakeholders 
about using an essential medicines list approach in Canada are not 
well understood. Various groups, including the pharmaceutical 
industry, have voiced concerns that an essential medicines 
approach could restrict choice or access to innovative medicines.19 
We sought to explore the perspectives of decision­makers and 
other key stakeholders on a possible national essential medicines 
list in Canada and to identify factors influencing the acceptability 
and feasibility of such a policy during an important pharmacare 
policy window using a qualitative study.
Methods
Data collection
Semistructured interviews were conducted by one author (J.D.J.) 
in English. We conducted interviews between July and September 
of 2018. The topic guide for our interviews (Appendix 1, available 
at www.cmaj.ca/lookup/suppl/doi:10.1503/cmaj.190567/­/DC1) 
was informed by Kingdon’s Multiple Streams Framework,20,21 
which depicts policy change as occurring when 3 streams — prob­
lems, policies and politics — come together at junctures termed 
“policy windows” (Figure 1; supplementary description in Appen­
dix 2, available at www.cmaj.ca/lookup/suppl/doi:10.1503/
cmaj.190567/­/DC1), as well as by data­collection tools used in 
research on essential medicines lists in Australia and Sweden.16,22 
A draft topic guide was shared with 4 experts on medicine 
priority­setting, both in Canada and at WHO, and refined based 
on their feedback. The topic guide included open­ended ques­
tions that addressed interview participants’ understanding of an 
essential medicines list, important processes for implementing 
an essential medicines list, and the roles of diverse stakeholders 
in this process (Appendix 1). The guide was used to prompt dis­
cussion, but interviews allowed for exploration of individual par­
ticipants’ perspectives and for unexpected themes to emerge.23 
We conducted one pilot interview and included it in the analysis, 
as no changes were made to the topic guide thereafter.
Our approach to sampling participants was also informed by 
the Multiple Streams Framework,20 which emphasizes the com­
plexity of policy­making shaped by diverse stakeholders at differ­
ent levels of government and outside of government. Thus, we 
purposively sampled key stakeholders in pharmaceutical policy 
with attention to Canada­wide representation from each of the 
following categories: federal government and pan­Canadian org­
anizations, provincial and territorial government, civil society and 
the private sector.24,25 Eligibility criteria for each category are 
shown in Table 1. Initial participants were identified using public 
documents and advice from experts; subsequent participants 
were identified through snowball sampling, whereby recruited 
participants were asked to suggest other eligible participants.25 
Our final sample size was determined by reaching thematic satu­
ration in data collection.26
No previous relationships existed between the interviewer 
and any of the participants. We obtained written informed con­
sent from all participants after discussing the purpose of the 
research (Appendix 3, available at www.cmaj.ca/lookup/suppl/
doi:10.1503/cmaj.190567/­/DC1). Where consent was not given 
for audio­recording, the interviewer took detailed field notes that 
included contextual information and nonverbal cues to incorpor­
ate into data analysis.27 One author (J.D.J.) and an assistant tran­
scribed all audio­recorded interviews verbatim. We deidentified 
and checked transcripts and field notes for accuracy.
Data analysis
We used inductive thematic analysis, in which only J.D.J. coded 
for emerging themes and concepts using NVivo 12, allowing 
themes to emerge from the data without a theoretical frame­
work, as described by Braun and Clarke.28 Codes and themes 
were then reviewed by A.M., N.P. and a research assistant to 
enhance interrater reliability and analytic credibility.28 We dis­
cussed the emerging themes in relation to the research question 
and the existing literature, whereby a continuous consultative 
approach between authors promoted reflexivity and enabled 
deep exploration of the themes.29 Negative cases were investi­
gated and discussed between all authors to test these themes 
and consider why they were different.30 
Policy window 
Problem stream  
• Features and indicators
(severity, metrics, anecdotes) 
• Focusing events 
Policy stream  
• Value acceptability 
• Technical feasibility 
Politics stream  
• Political feasibility 
• Balance of interests 
• National mood 
Figure 1: Kingdon’s Multiple Streams Framework (adapted, with permis­
sion, from Jones et al.21). The problem stream involves policy issues that 
diverse stakeholders pay attention to and desire action on. The policy 
stream describes viable policy solutions or instruments to solve policy 
problems. The politics stream describes decision­maker motives and 
opportunities to advance policy, influenced by factors such as interest 
groups and perceived political feasibility.20
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After developing a coding framework, J.D.J. conducted deduc­
tive analysis using the Multiple Streams Framework,20 whereby 
the framework’s 3 established categories and considerations, 
such as value acceptability and technical feasibility within the 
policy stream (Figure 1), served to organize the analysis and theo­
retical comparison of inductive themes.21 The deductive analysis 
and findings were reviewed by A.M., P.P. and N.P. Disagreements 
in interpretation of the themes or findings were discussed among 
the authors to arrive at a shared interpretation. Considered in the 
reflexive approach were researchers’ characteristics that included 
our diverse experiences in pharmaceutical policy, patient care 
and health systems research in Canada and internationally.29 
When designing the study and interpreting the results, we con­
sidered and tried to balance with alternative views the following 
perspectives: J.D.J. and N.P. have collaborated in the past with 
the WHO Essential Medicines List secretariat, and N.P. is studying 
and has advocated for an essential medicines list approach in 
Canada. Finally, we shared the research findings with 2 study par­
ticipants who reviewed and validated the findings based on their 
inputs into the study.31 We followed the Consolidated Criteria for 
Reporting Qualitative Research guidelines.24
Ethics approval
We obtained ethics approval through the London School of 
Hygiene & Tropical Medicine Ethics Committee (Ref: 15365).
Results
Participants
We conducted a total of 21 interviews (Table 1). J.D.J., A.M. and N.P. 
continuously reviewed emerging themes and agreed that satura­
tion was reached at this point.26 We sent email invitations for inter­
views to 39 individuals across 13 provinces and territories. Five peo­
ple did not respond to the request for interview, and 13 declined 
because of perceived conflicts of interest or time constraints; 3 of 
these 13 referred a colleague. Seventeen interviews were con­
ducted over the phone and 4 in person, lasting 40–80 minutes each. 
Written consent was obtained for audio­recording interviews from 
18 participants. Participants represented 6 diverse provinces and 
territories, including 5 diverse provincial or territorial governments. 
Nine participants were women and 12 were men.
Themes identified fell under 3 categories: perceptions of the 
problem, perceptions of the essential medicines list as a policy 
solution and the politics of an essential medicines list. Table 2 
summarizes factors identified influencing acceptability and feas­
ibility of an essential medicines list, along with quotes.
Perceptions of the problem
There was consensus on a problem: the prescription­medication 
needs of all Canadians are not being adequately met. Respon­
dents’ views on the most important features of the problem dif­
fered. The features most frequently cited were inequitable 
access to medicines, high drug prices and health system ineffi­
ciencies. There was consensus on the need to address current 
inequitable access to medicines and variations in medication 
affordability across the country. The second key challenge that 
arose was access to affordable medicines as a key component of 
a more sustainable and efficient health care delivery system.
Policy content and process factors
Five themes emerged across the content and process categories 
that may affect acceptability and feasibility of an essential medi­
cines list in Canada.
No shared understanding or definition of essential medicines 
or an essential medicines list
Some did not view an essential medicines list as applicable in the 
Canadian context, owing to a perceived difficulty in agreeing on a 
set of medicines that would sufficiently cover the needs of all 
Canadians or owing to an association of the concept with WHO 
and lower­income countries. Those who voiced a more global 
view of essential medicines voiced less opposition to an essential 
medicines list and saw this idea as synonymous with a formulary 
or as a “specific kind of formulary” (FED4). Many respondents 
Table 1: Participant eligibility and participation
Participant category Eligibility criteria
Participants invited
Interviewed
Declined or 
did not reply
Federal government or pan­Canadian 
institutions 
Senior officials involved in decision­making related to 
prescription drug coverage, serving in federal departments or 
pan­Canadian agencies
5 4
Provincial or territorial government Senior officials in positions of decision­making across diverse 
provincial and territorial authorities in Canada; portfolio 
includes prescription drug coverage
5 9
Civil society Active nongovernmental stakeholders in national pharmacare 
discussions with public health mandate; senior 
representatives of health care professional bodies, 
nongovernmental organizations, unions; academics
9 3
Private sector Senior representatives of private industry organizations that 
appear influential in national pharmacare discussions
2 2
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Table 2 (part 1 of 2): Perceived factors influencing the acceptability and feasibility of an essential medicines list in Canada 
through the lens of Kingdon’s Multiple Streams Framework
Stream Factors identified Example quotes
Perceptions of the 
problem (problem 
stream)
 
Inequitable access to 
medicines across Canada
“I think number one, that those challenges [to providing prescription drugs] probably look 
differently depending on which province you’re in, right. That’s one of the challenges of who 
we cover, how we cover, and in some cases what we cover look different.” — PT5
Health system 
sustainability concerns 
(including high medicine 
costs)
“Canada pays among the highest prices for medicines in the world. ... And Canada’s gotta 
equip itself with the institutional capacity to push back and to make sure our prices remain 
reasonable. And in some sense the most clinically and economically rational way of doing 
that is through the careful evidence­based negotiation of what gets covered and at what 
price is it covered.” — CSO1
“... there’s a huge amount of inefficiency for the sake of jurisdictional autonomy.” — FED4
Policy content and 
process factors (policy 
stream)
 
 
 
 
 
 
 
 
 
 
 
 
Content
No shared understanding 
of an essential medicines 
list and how to define 
essential medicines
 
 
 
“I don’t think the public understands. And I use public not only the person on the street, but 
other sort of stakeholders in the health care system. I don’t think they have an agreement of 
what that list means, and even I don’t know if I know what that means.” — PT5
“To me that is a policy approach that is used more for developing countries and is potential 
confusing term in developed countries like Canada.” — PT4
Examples of the 2 most common ways that essential medicines were defined:
• “the shortest possible list of critical medicines that are needed in a jurisdiction in order to 
meet the primary, common and serious health needs of the population.” — CSO7
• “Until you’re sick, you really do not know what you would consider essential. When you’re 
sick, everything is essential that you need to get better.” — CSO9
Concerns around 
therapies that would be 
excluded from the 
essential medicines list
“Often anything taken away is a bad thing. Even if it was causing harm, but if one person 
benefited, they will see it as a bad thing. If the new list is much smaller and less, it will be 
seen as less benefit for the person.” — FED2
“So what happens to those other ones, right? All the people using those. So the tension that 
that would create to maintain an essential drug list ... everyone will want to be deemed 
essential, right?” — PT4
Process
Need for an independent 
and accountable 
decision­making body
 
“If it’s going to be national, some sort of pan­Canadian body or bodies that report into one 
central mechanism. And it would need representatives from clinical community, patients, 
caregivers, family members, public, methodologists — the people who will do evidence 
synthesis, systematic reviews, pharmacists ... and we would need people who were 
representing jurisdictions, so the drug plan managers. But again, not political people. And 
likely also specific representation from the First Nations community. ... And they should 
have very clear terms of reference, publicly announced meetings, you know whether their 
deliberations should become public. ... you would need to make sure that everybody 
engaged would disclose conflicts of interest and those are managed appropriately, which 
could mean excluding anybody with conflicts. I would say ... that there would not be reps 
from industry on this [decision­making body].” — FED5
Clear and agreeable 
selection factors for the 
development and 
management of a list: 
clinical evidence and 
cost­effectiveness
“... if it’s truly marginally beneficial, why the heck is someone even considering to pay for it 
today, whether it’s public or private?” — IND1
“It’s not all or nothing, but the degree to which you fund a drug, and how much of that drug 
you fund, depends on how much evidence you have for benefit for that population.” — FED4
“... it’s an exercise about trying to make good judgments about what investment in which 
drugs at any particular point in time will provide the best outcome for the patient. And at 
what cost should that occur? At what cost should that investment come.” — CSO8
Framing and 
communication of an 
essential medicines list
“This is not about restricting access to medicines for people, it’s about improving access to 
medicines. There are a lot of people who do not have access to the meds that would be on 
an essential medicines list at all. So thinking about how you frame it I think also matters.” 
— CSO7
“... you have to put it into a language where we will guarantee Canadians that the 
prescription drugs that will be put on the list will be scientifically proven, evidence based ... 
and efficient, and better prescribing habits. ... It doesn’t matter if it’s 2 drugs or 10 000, but 
what’s on that list is what you will need based on what the experts are saying and that’s that 
guarantee we need to give.” — CSO6
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suggested that the use of another term to replace “essential 
medicines” might result in more support for the concept. The 
most common views articulated on what essential medicines 
meant was either medicines most commonly required by the 
population or those medically required by a given individual.
Concerns about what is not listed on an essential medicines list
Concerns about what would be excluded from an essential medi­
cines list were voiced across all participant categories. Stakeholders 
voiced their perceptions of the public’s response to an essential 
medicines list either stating that “people don’t want their choice 
restricted” (FED3) or they described perceived opposition from spe­
cific stakeholders, namely, rare­disease patient groups, pharmaceu­
tical and insurance industries, or certain clinicians. Others perceived 
that an essential medicines approach might result in coverage being 
taken away from some Canadians under their current private or 
public plans or that it would be “very restrictive” (IND2).
Most strongly emphasized by respondents from provincial 
and territorial governments and industry, and by some from civil 
society, was that an essential medicines list might not offer a suf­
ficiently dynamic approach to address “the big elephant in the 
room” (PT5) of how to handle access to high­cost, specialized or 
novel therapeutics. In particular, provincial and territorial 
decision­makers noted concerns about “creating 2 tiers by creat­
ing an essential medicines list, because every province is still 
gonna struggle with how to cover what’s not on the list” (PT2).
An independent and accountable decision-making body
There was strong consensus around the need for an independent 
decision­making body, with frequent mention by interviewees of a 
multidisciplinary and multistakeholder “arm’s­length” agency and a 
committee (or committees) that would oversee the management 
and medicine­listing decisions of an essential medicines list. Key 
stakeholders to involve in the process were considered to be clin­
icians, patients and the public, provincial and territorial drug­plan 
representatives, payers (primarily governments) and experts “who 
can evaluate the evidence” (FED3). However, many also noted the 
tension between engagement and efficiency: “sometimes you weigh 
yourself way too down by having too many fingers in the pot” (PT5).
Core selection criteria for an essential medicines list
There was consensus among interviewees on selection factors 
that could serve as core, transparent criteria for selecting medi­
cines to be included in an essential medicines list. First, that 
decisions be based on the best available evidence for clinical and 
health outcomes above all other considerations, particularly for 
drugs for which decision­making might be difficult in the face of 
limited or contested evidence. Second, that cost­effectiveness 
and value for money must be considered. A shared priority was 
to maintain a sustainable model that carefully weighs the evi­
dence and added value of high­cost therapeutics. Many concerns 
existed around money currently spent on products in which the 
evidence is “complete crap” (CSO2). Several participants noted 
the need to evaluate societal benefit that interventions offer and 
to better understand opportunity costs incurred, which were a 
particular concern for government respondents.
Framing and communicating to the public and decision-makers
How an essential medicines list is framed and communicated to the 
public, clinicians, pharmacists and decision­makers was voiced as a 
key factor influencing the acceptability of an essential medicines 
list. Many interviewees remarked that an essential medicines list 
would be more acceptable to important stakeholders if it were 
clearly emphasized as a means to improve equitable access to 
Table 2 (part 2 of 2): Perceived factors influencing the acceptability and feasibility of an essential medicines list in Canada 
through the lens of Kingdon’s Multiple Streams Framework
Stream Factors identified Example quotes
Political factors 
(politics stream)
Federal financing and the 
pharmacare model
“[Federal financing for] perhaps a half of the costs of that formulary, which is sort of the medicare 
bargain: the feds pay half, the provinces pay half, at the outset of Canadian medicare.” — CSO1
“[Who should decide] depends on who is paying the bills. And that’s the real challenge right 
now, is that you have all these different payers, right. If one group actually wants to take that 
on, then they would be accountable for that process. ... but we would have [to] rely on a 
national approach that actually looks at formulary management besides just the drugs that 
are being submitted [to CADTH]. ... And if it is decentralized, then the jurisdictions should 
have the right to manage their own formulary.” — PT4
Management of diverse 
stakeholder interests and 
safeguards against 
conflicts of interest by an 
independent body
“You also absolutely need to insulate the people involved in making the final decisions about 
what’s on and what’s off from political pressures. And I believe firmly that’s a benefit to our 
political leaders, because they are vulnerable as representatives of particular constituents ... to 
threats by industry stakeholders that they will withhold funding, they will withhold industrial 
projects, they will withhold research activities, they will lay off people working in their 
workforces, if a decision doesn’t go their way. ... It’s a form of political extortion, right.” — CSO1
“I think it’s critical to have citizen involvement. I don’t think that these things should be 
done just by so­called experts. How you select the citizens who get involved in that, that 
they don’t have a particular bone to pick or a particular disease that they care about, is 
always very tricky. But it’s not an excuse not to have citizen involvement.” — CSO7
Note: CADTH = Canadian Agency for Drugs and Technologies in Health, CSO = civil society, FED = federal government or pan­Canadian institutions, IND = private sector, PT = provincial 
or territorial government.
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evidence­based, high­quality and affordable medicines. The diffi­
culty communicating the idea effectively, given the diverse under­
standings and ideas around what essential medicines and an essen­
tial medicines list mean, was acknowledged. Nevertheless, several 
participants were optimistic that most Canadians would respond 
favourably to clear communication on an essential medicines list.
Political factors
There was consensus among participants that federal financing 
would be necessary to formulate, implement and sustain an 
essential medicines list. Provincial and territorial government 
respondents considered that final decisions related to medicines 
publicly covered should rest with the government that is paying, 
many seeing decision­making power as something that would 
likely remain with provincial and territorial governments. Possible 
pharmacare models were mostly discussed as either a single­
payer system or a “fill the gaps” approach to the current system. 
No clear pattern was observed between participants’ views on the 
feasibility of an essential medicines list and links to or preferences 
for a particular pharmacare model. A few respondents referred to 
an essential medicines list as a stepping stone or “political tool” 
(CSO1) to implement universal single­payer pharmacare.
Most participants, particularly those from civil society, voiced con­
cerns around the influence of groups with vested interests, such as 
patient groups funded by pharmaceutical industry. Several provincial 
and territorial government respondents noted industry’s attempts to 
“consistently and continuously” (PT5) influence policy at the provin­
cial and territorial government level. Some noted the importance of 
instituting “a perpetual [government] commitment that survives 
changes in the political cycle” (CSO8) at federal, provincial and terri­
torial government levels. Engagement of patients and the public to 
provide meaningful and deliberate input into processes was deemed 
important by most, and this engagement was often seen as a method 
to increase transparency. Participants emphasized the need to man­
age conflicts of interest carefully to ensure that voices heard were rep­
resentative of all Canadian concerns and needs.
Interpretation
Decision­makers and key stakeholders in Canada had different and 
sometimes skeptical views on the suitability of an essential medi­
cines list in Canada. Nonetheless, there was consensus on 3 impor­
tant factors that would need to feature in the policy process of a 
possible approach to an essential medicines list: an independent 
decision­making body, selection criteria to list medications based 
primarily on clinical and cost­effectiveness, and clear communica­
tion with the public on the purpose and evidence­based focus of 
the essential medicines list.
A lack of shared understanding of the concept of the essential 
medicines list and diverse opinions on what constituted an “essential 
medicine,” based either on what is considered essential for the popu­
lation or for the individual, were also found in a similar study in Aus­
tralia, raising questions about the perceptions about essential medi­
cines lists in high­income countries.22 A study of key elements of 
Sweden’s Wise List highlighted 3 of the same process factors identi­
fied in this study: comprehensive communication and branding of 
the list, an independent decision­making body, and strict medicine­
selection criteria (along with audience­targeted Wise List editions). 
The Swedish list was first implemented in 2000 and is widely 
accepted by physicians and the public.16,17 Branding a Canadian 
essential medicines list might be important given some negative 
associations with the term, and Sweden’s Wise List could be an 
example to emulate. Similar to the need for an independent body to 
develop and manage a possible essential medicines list that 
emerged in this study, other reports have recommended the creation 
of an arm’s­length body as a key component of pharmacare infra­
structure.7,32 The Federal Advisory Council on the Implementation of 
National Pharmacare’s recent recommendations for universal, 
 single­payer public pharmacare to be implemented through federal 
leadership, in partnership with provinces and territories, also include 
a “Canadian drug agency” and suggest that implementation of a 
national formulary should begin with coverage for a list of essential 
medicines.10 Furthermore, trusted institutions and processes cur­
rently exist across public formularies and through bodies such as the 
Canadian Agency for Drugs and Technologies in Health, which can be 
used to develop an essential medicines list or national formulary.
Limitations
As with most qualitative research, we cannot claim that our find­
ings are representative of all stakeholder views or generalizable 
beyond our study population. For example, it is possible that non­
respondents may hold negative views on an essential medicines 
list. However, many decision­makers who declined to participate 
did so because of perceived conflicts of interest in the context of 
their concurrent contributions to the consultations of the Federal 
Advisory Council on the Implementation of National Pharmacare 
in 2018, which ultimately recommended a list of essential medi­
cines as an intermediary for a comprehensive national formu­
lary.10 We did not directly interview patients, caregivers or com­
munity members, who represent important voices in this context, 
although public and prescriber perceptions on an essential medi­
cines list have been captured to some extent elsewhere.33,34 
Some variations in data­collection methods may have affected 
the findings. First, for study feasibility, the interview setting was pri­
marily over telephone; although this is a valid method to collect 
interview data,35 it may have affected rapport and candor compared 
with in­person interviews. Careful attention was given to establish 
rapport in each interview.27 Second, field notes data from the 3 inter­
views that were not audio­recorded may have lacked rich descrip­
tions present in transcript data, which may have resulted in some 
codes or themes being missed. Detailed field notes were taken dur­
ing and after these interviews to capture responses as best possible.27
Conclusion
Although stakeholders’ views on the suitability and content of a Can­
ad ian essential medicines list varied, there was consensus on the pro­
cess to formulate and implement such a list or common national for­
mulary. The concept of selecting priority medicines based on the best 
evidence appeared to be widely supported but probably requires 
careful communication with diverse stakeholders. Further work is 
needed to establish understanding of how patients, clinicians and the 
public perceive the concept of a Canadian essential medicines list.
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